ClinicalTrials.gg
TerminatedNCT04803058PERSPECTIVEUpdated Jul 13, 2026

A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)

A Phase 2 interventional study of TCD601 in Kidney Transplantation, sponsored by ITB-Med LLC. Terminated at 3 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by ITB-Med LLC · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision, indication no longer under evaluation

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate if TCD601 can induce allogeneic tolerance in living donor renal transplant recipients

02

Conditions studied

  • Kidney Transplantation
03

In context

Lead sponsor

ITB-Med LLC is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Able to understand the study requirements and provide written before any study assessment is performed
  • Male or female patients ≥ 18 to 65 years of age
  • Recipient of a renal transplant from a non-human leukocyte antigen (HLA)-identical but at least haploidentical, ABO compatible living donor

Key Exclusion Criteria:

  • Women of , unless willing to comply with the use of highly effective methods of as defined by the protocol
  • A history of cancer other than basal cell carcinoma of the skin or carcinoma in situ of the cervix
  • Recipient with anti-HLA donor-specific antibody (DSA)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Arm 1

    TCD601administered with non-myeloablative conditioning and standard of care immunosuppression

    Biological: TCD601

Interventions

  • BiologicalTCD601

    Investigational Product

06

What researchers measure

Primary outcomes

  1. The safety, tolerability and activity of a Siplizumab-based conditioning regimen to induce renal allograft tolerance

    The proportion of patients off immunosuppression with good safety and tolerability

    Time frame: 24 months

Secondary outcomes

  1. Incidence of biopsy proven acute rejection, death, and graft loss

    Time frame: 24 months

  2. The incidence of DSA

    Time frame: 24 months

07

Study locations

3 sites
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Samsung Medical University
    Seoul, South Korea
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Feb 2026, 38 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2021
First posted
Mar 17, 2021
StartActual
Dec 14, 2022
Primary completionActual
Feb 17, 2026
CompletionActual
Feb 17, 2026
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04803058
Lead sponsor
ITB-Med LLC
Responsible party
Sponsor
First posted
Mar 17, 2021
Start date
Dec 14, 2022
Primary completion
Feb 17, 2026
Completion
Feb 17, 2026
Last update
Jul 13, 2026

Study contacts

Tracy Killingsworth
study director · Nefro Avillion

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Siplizumab

Start the discussion